Brian Buntz
Brian Buntz covers pharma, biotech and research with a data-driven, technology-forward lens that connects drug discovery to applied AI and the broader R&D economy. He leads editorial across R&D World and Drug Discovery & Development, shaping coverage that spans pharmaceutical innovation, biotech financing and laboratory technology. His work is marked by original datasets, deep sourcing and technical context that show how scientific advances, business models and automation reshape health and life sciences.
Pharma pipelines, policy and commercial strategy
At Drug Discovery & Development, Buntz reports on how policy and market forces affect pharmaceutical R&D, including tariffs on patented medicines that extend from large manufacturers to mid-sized and smaller drugmakers and their research budgets. He builds industry-scale rankings such as the 50 best-funded biotech companies of 2026, tracking cumulative equity, latest financings, therapeutic focus and development stage for private firms that meet his funding screens.
His Pharma 50 work ranks the largest pharmaceutical companies by revenue using primary filings, giving readers a comparable view of performance over multiple fiscal years. He follows commercial execution as closely as science, highlighting how vendor selection in pharma still relies on word of mouth and profiling efforts like Rx Almanac that aim to bring data discipline to those decisions.
Across these pieces he treats pipelines, pricing, funding and commercialization as parts of the same system, drawing clear lines between capital flows and the medicines reaching patients.
AI, automation and research infrastructure
Buntz’s beat extends across applied AI and lab technology, where he chronicles how computation and automation transform research and care. His coverage of Talus Bio explains a drug screening platform that claims 5,000-fold speed improvements by skipping protein folding and targeting transcription factors, framed against the impact of tools like AlphaFold on structural biology.
In work comparing Alphabet and Meta’s R&D spending with that of the ten largest drugmakers, he shows how Big Tech now invests at levels comparable to pharma, underscoring convergence between software, data and therapeutics.
His broader remit includes AI in pharma, lab automation, analytical instrumentation, surgical robotics and national lab research, tying each technology back to the workflows and institutions that conduct physical-science R&D. He has investigated national science funding, such as budget cuts at the National Science Foundation and their impact on the U.S. research workforce, treating policy as part of the infrastructure that enables or constrains innovation. Deep dives into subjects like xAI’s “Colossus” supercluster build-out and humanoid robotics sit alongside his health coverage, reflecting an interest in the computing and hardware layers that future biomedical advances will rely on.
Behind the scenes, he designs AI-enabled editorial workflows and custom data pipelines to identify innovative companies and forecast R&D intensity, then brings those models into narrative features.
Profiles of innovators in drug discovery and precision medicine
Buntz regularly centers his coverage on scientists and executives pushing new approaches to drug development.
His award-winning interview feature with Genoskin’s Eric Merle explores how human tissue from surgical procedures can replace animal testing in preclinical work, treating that shift as both a scientific and ethical inflection in drug discovery. In a special feature on mRNA technology, he looks beyond COVID-19 vaccines to its potential applications in cardiology, oncology and other infectious diseases, balancing technical explanation with clinical promise.
He has recapped trends from major healthcare meetings such as the J.P. Morgan Healthcare Conference, including Switch Therapeutics’ RNA interference programs and the wider push toward precision medicines that target diseases at the genetic level. His interview with Bo Wang, now a senior biomedical AI leader, covers foundation models for healthcare and biology and the challenge of matching novel treatments to patients most likely to respond.
Coverage of Inductive Bio’s ADME-One platform examines how pre-competitive data consortia and high-performing ADMET and pharmacokinetic models can deliver early human PK reads and bundled Tier 1 ADME assays at accessible price points. Across these stories he uses long-form interviews and technical detail to show how specific companies, tools and scientific ideas fit into larger trends in precision medicine and computational drug discovery.
Health and neuroscience research reporting
Beyond trade and technology coverage, Buntz also writes about primary health research. In his News-Medical reporting on Indiana University work into immune cell aging in Parkinson’s disease, he follows how changes in the immune system may contribute to neurodegeneration and what that implies for future interventions in movement disorders. That kind of piece adds bench-level neuroscience and immunology to his portfolio, linking mechanisms of disease back to the clinical and translational questions that drive new therapies.
Long-tenure B2B journalism and medtech roots
Buntz brings nearly two decades of B2B editorial experience to his current health and R&D coverage, with a background spanning healthcare, medical devices, cybersecurity and industrial technology.
Before taking on his present leadership roles, he held senior editorial and content positions at publishers that focused on connected devices, AI, Industry 4.0 and medical devices, building a familiarity with regulated technologies and complex engineering that now informs his treatment of surgical robotics and laboratory systems. That mix of medtech, security and industrial automation coverage gives his health stories a systems perspective, situating new drugs and digital tools inside the technical stacks and operational constraints of hospitals, labs and manufacturers. His recognition with a national gold Azbee Award for a pharma feature underscores that he not only tracks these domains closely but can synthesize them into narrative work that stands out among business-to-business science publications.
4 more health journalists.
Aislinn Antrim
Aislinn Antrim is an associate editorial director at Pharmacy Times and a journalist who connects clinical advances, regulation, and the changing role of pharmacists. She writes pharmacy-centered health coverage on chronic disease therapeutics, specialty and oncology care, workforce pressures, and advocacy. Her reporting explains FDA actions, policy shifts, drug pipelines, and the real-world effects of new evidence on patient care and pharmacy practice. She often uses interviews and expert conversations to show how pharmacists improve adherence, manage side effects, navigate access and benefits, and coordinate care with prescribers. She also covers burnout, staffing strain, and the future of pharmacy practice, with an eye on how policy and economics shape work at the dispenser.
Alex Cabrero
Alex Cabrero is an Emmy award-winning KSL TV reporter who covers where health, safety and community life meet, always focused on how decisions and events affect everyday people. He has been with KSL since 2004, bringing long experience in breaking news, public service coverage and human-centered features. His beat includes public health, emergency response, technology, local infrastructure, environment and science, framed through community well-being and resilience. He reports on issues like mental health initiatives, law enforcement staffing, environmental hazards, rescues, wildfire detection tools, land-use fights and scientific discoveries, making technical and policy details clear for a general audience. He also produces many positive, everyday-life features on families, veterans, farmers, sports and local traditions. His style is direct and conversational, often built around a central person or family whose experience carries the story across TV, digital and social platforms.
Alexandra Frost
Alexandra Frost is a freelance journalist and content marketing writer who turns expert-backed health and family guidance into clear, practical service stories. She covers consumer health, wellness, nutrition, preventive care, medical research, parenting, kids’ mental health, education, products, and lifestyle. Her reporting explains concerns such as inflammation, urinary symptoms, fiber, lung cancer screening, pain treatment, mobility, family dynamics, children’s technology use, and school readiness. She profiles clinicians and scientists, connects research to everyday decisions, and focuses on what readers should watch for, ask, or change. Frost currently writes across multiple outlets, including Good Housekeeping, Cincinnati Magazine, Wirecutter, Popular Science, Success, Healthline, Parents, Women’s Health, Reader’s Digest, Today’s Parent, the Atlantic, the Washington Post, TIME, Consumer Reports, Business Insider, and National Geographic. She also works as a freelance editor, media consultant, and content strategist.
Alexandra Pattillo
Alexandra Pattillo is a freelance journalist who pairs rigorous health and science reporting with intimate accounts of patients’ lives. She covers health, science and wellness for the BBC and other major outlets, including National Geographic, The New York Times, The Atlantic, The Guardian, Outside, CNN and Inverse. Her beat includes eating disorders, women’s health, perinatal mental health, brain health, youth sports, concussion, long-term Covid symptoms, attention, habits and behavioral science. She reports on emerging treatments such as psychedelic-assisted therapy for anorexia, testing evidence, safety and relapse risk. She explains complex research in plain language and examines how it shapes everyday choices. Her reporting uses in-depth interviews with patients, families, clinicians, researchers and coaches. Through the BBC’s Health Gap column, she also covers stigma, unequal access to care and gaps between lived experience and standard medical pathways.